HealthQuill Priority Review
The US Food and Drug Administration has approved Nuvation Bio Inc.’s medicine for adults who have a rare type of lung cancer caused by a specific genetic change.
Drugs Health Pharma

US drug regulator greenlights Nuvation’s rare lung cancer medicine

HQ Team June 11, 2025: The US Food and Drug Administration has approved Nuvation Bio Inc.’s medicine for adults who have a rare.

Read More
British-Swedish AstraZeneca’s drug for treatment of a form of blood cancer has been granted a Priority Review in the US by the drug regulator.
Drugs Health Pharma

AstraZeneca’s experimental blood cancer drug gets US priority review

British-Swedish AstraZeneca’s drug for treatment of a form of blood cancer has been granted a Priority Review in the US by the drug.

Read More
AstraZeneca and Daiichi Sankyo got a priority review from the Food and Drug Administration for their Enhertu drug to treat a form of breast cancer in the US.
Drugs Health Pharma

AstraZeneca, Daiichi’s Enhertu drug gets FDA’s priority review in US

AstraZeneca and Daiichi Sankyo got a priority review from the Food and Drug Administration for their Enhertu drug to treat a form of.

Read More
he US Food and Drug Administration has given the green light to Merck’s vaccine to protect adults against the different types of bacteria that cause invasive pneumococcal disease.
Drugs Health Pharma

Merck’s vaccine for pneumococcal disease gets FDA’s green light

The US Food and Drug Administration has given the green light to Merck’s vaccine to protect adults against the different types of bacteria.

Read More
Merck’s Biological Licence Application for a pulmonary arterial hypertension drug has been accepted for a priority review by the FDA.
Drugs Health Pharma

Merck gets priority review nod from USFDA for hypertension drug 

HQ Team September 28, 2023: Merck’s Biological Licence Application for a pulmonary arterial hypertension drug has been accepted for a priority review by.

Read More